Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Intra-Cellular Therapies stock
Own Intra-Cellular Therapies stock in just a few minutes.
Intra-Cellular Therapies, Inc is a biotechnology business based in the US. Intra-Cellular Therapies shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intra-Cellular Therapies employs 383 staff and has a trailing 12-month revenue of around USD$22.8 million.
How to buy shares in Intra-Cellular Therapies
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Intra-Cellular Therapies. Find the stock by name or ticker symbol: ITCI. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intra-Cellular Therapies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intra-Cellular Therapies, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Intra-Cellular Therapies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Intra-Cellular Therapies share price
Use our graph to track the performance of ITCI stocks over time.Intra-Cellular Therapies shares at a glance
Information last updated 2021-04-08.
| 52-week range | USD$15.9974 - USD$40.005 |
|---|---|
| 50-day moving average | USD$34.8715 |
| 200-day moving average | USD$30.2393 |
| Wall St. target price | USD$51.38 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.814 |
Buy Intra-Cellular Therapies shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Intra-Cellular Therapies stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Intra-Cellular Therapies financials
| Revenue TTM | USD$22.8 million |
|---|---|
| Gross profit TTM | USD$-44,864,187 |
| Return on assets TTM | -29.84% |
| Return on equity TTM | -53.3% |
| Profit margin | 0% |
| Book value | $8.163 |
| Market capitalisation | USD$2.6 billion |
TTM: trailing 12 months
Shorting Intra-Cellular Therapies shares
There are currently 6.3 million Intra-Cellular Therapies shares held short by investors – that's known as Intra-Cellular Therapies's "short interest". This figure is 1.5% down from 6.4 million last month.
There are a few different ways that this level of interest in shorting Intra-Cellular Therapies shares can be evaluated.
Intra-Cellular Therapies's "short interest ratio" (SIR)
Intra-Cellular Therapies's "short interest ratio" (SIR) is the quantity of Intra-Cellular Therapies shares currently shorted divided by the average quantity of Intra-Cellular Therapies shares traded daily (recently around 624230.73891626). Intra-Cellular Therapies's SIR currently stands at 10.15. In other words for every 100,000 Intra-Cellular Therapies shares traded daily on the market, roughly 10150 shares are currently held short.
However Intra-Cellular Therapies's short interest can also be evaluated against the total number of Intra-Cellular Therapies shares, or, against the total number of tradable Intra-Cellular Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intra-Cellular Therapies's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Intra-Cellular Therapies shares in existence, roughly 80 shares are currently held short) or 0.0877% of the tradable shares (for every 100,000 tradable Intra-Cellular Therapies shares, roughly 88 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Intra-Cellular Therapies.
Find out more about how you can short Intra-Cellular Therapies stock.
Intra-Cellular Therapies share dividends
We're not expecting Intra-Cellular Therapies to pay a dividend over the next 12 months.
Intra-Cellular Therapies share price volatility
Over the last 12 months, Intra-Cellular Therapies's shares have ranged in value from as little as $15.9974 up to $40.005. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intra-Cellular Therapies's is 1.3398. This would suggest that Intra-Cellular Therapies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intra-Cellular Therapies overview
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert